Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sos, Martin L., Michel, Kathrin, Zander, Thomas, Weiss, Jonathan, Frommolt, Peter, Peifer, Martin, Li, Danan, Ullrich, Roland, Koker, Mirjam, Fischer, Florian, Shimamura, Takeshi, Rauh, Daniel, Mermel, Craig, Fischer, Stefanie, Stückrath, Isabel, Heynck, Stefanie, Beroukhim, Rameen, Lin, William, Winckler, Wendy, Shah, Kinjal, LaFramboise, Thomas, Moriarty, Whei F., Hanna, Megan, Tolosi, Laura, Rahnenführer, Jörg, Verhaak, Roel, Chiang, Derek, Getz, Gad, Hellmich, Martin, Wolf, Jürgen, Girard, Luc, Peyton, Michael, Weir, Barbara A., Chen, Tzu-Hsiu, Greulich, Heidi, Barretina, Jordi, Shapiro, Geoffrey I., Garraway, Levi A., Gazdar, Adi F., Minna, John D., Meyerson, Matthew, Wong, Kwok-Kin, Thomas, Roman K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2009
Schlagworte:
Technical Advance
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2689116/
https://ncbi.nlm.nih.gov/pubmed/19451690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI37127
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge